Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2741a Phase 1 study in healthy volunteers and atopic dermatitis
NCT04211415Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of DS-2741a in atopic dermatitis (AD) (11 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Incidence of adverse events among participants receiving DS-2741a up to 4 weeks, Maximum plasma concentration (Cmax) of plasma DS-2741a at Day 49 and 7 more. Started Jan 2020; status: terminated.
02
Drugs
DS-2741a
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04211415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211415.